Alert! We've detected that your cookie settings are disabled.
In order to achieve an optimal browsing experience, please enable your cookie settings.
For instructions on how to enable your cookie settings:
Click here for cookie settings
Click here for JavaScript settings
THE PHARMACIST'S NEWS SOURCE
Follow Us FB Twitter  Last Update: July 31, 2014
Email Register | Forgot Password
Password Remember me
       

FDA Approves Zydelig for Three Types of Blood Cancers

August 2014

ROCKVILLE, Md.—The FDA granted accelerated approval to idelalisib (Zydelig, Gilead) to treat patients with three types of blood cancers, but the product carries a Boxed Warning about serious adverse events.
read more

  • FDA Approves Zydelig for Three Types of Blood Cancers

    August 2014

    ROCKVILLE, Md.—The FDA granted accelerated approval to idelalisib (Zydelig, Gilead) to treat patients with three types of blood cancers, but the product carries a Boxed Warning about serious adverse events.
    read more

  • FDA Approves Dalbavancin for Skin Infections

    July 2014

    The FDA has approved dalbavancin, a second-generation glycopeptide, for the treatment of gram-negative acute bacterial skin and skin structure infection (ABSSSI). The approval comes on the heels of two large trials that showed ...
    read more

  • Rivaroxaban Beats Injectable on Cost-Effectiveness

    July 2014

    Rivaroxaban was more cost-effective than other anticoagulants for inpatient use in two retrospective studies that included patients undergoing joint replacement as well as those with atrial fibrillation or venous thromboembolism. One expert predicted, however, that insurance issues and less ...
    read more

The Most Read Articles From